Efficacy of nintedanib on severe COVID-19 pneumonia.

Phase 2

• Conditions: Severe pneumonia induced by COVID-19; COVID-19

• Registration Number: JPRN-jRCTs051200036
• Lead Sponsor: memura Yutaka

Brief Summary

Thirty patients were in nintedanib group and 30 patients were in control group. There were no significant differences in 28-day mortality between the groups. Lengths of mechanical ventilation were significantly shorter in the nintedanib group. Computed tomography volumetry showed that the percentages of high-attenuation areas were significantly lower in the nintedanib group.These finding suggested that the administration of nintedanib may offer potential benefits for minimizing lung injury in COVID-19.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-27
• Study Completion: 2020-10-01
• Results First Posted: 2021-05-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1) Obtaining sufficient informed consent for this trials from participates or their close relatives
2) 20 years or older at the time of informed consent
3) Confirmed COVID-19 by PCR assay or LAMP assay
4) Respiratory failure requiring mechanical ventilation
5) Availability of a nasogastric tube

Exclusion Criteria

1) History of Idiopathic pulmonary fibrosis
2) History of chronic liver failure (Child Pugh B or C)
3) Breastfeeding and pregnancy
4) History or proven risk factors of thrombosis
5) Proven risk factors of bleeding
6) Unavailable to use enteral tube
7) Ineligibility for other reasons

Study & Design

• Study Type: Interventional
• Study Design: Not specified